Cargando…

NEAT HFpEF: Organic nitrates fail to deliver

Detalles Bibliográficos
Autores principales:	Wagdy, Kerolos, Hassan, Mohamed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Magdi Yacoub Heart Foundation 2016
Materias:	Lessons from the Trials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642815/ https://www.ncbi.nlm.nih.gov/pubmed/29043251 http://dx.doi.org/10.21542/gcsp.2016.1

Ejemplares similares

Towards tailoring blood pressure control in HFpEF: Lessons from OPTIMIZE-HF
por: Hassan, Mohamed
Publicado: (2019)

TOPCAT misses its primary endpoint: Should spironolactone be abandoned in HFpEF?
por: ElGuindy, Ahmed M.
Publicado: (2013)

DELIVER: Extending the benefits of SGLT-2 inhibitors
por: Samaan, Kerollos, et al.
Publicado: (2023)

ASGR1 - a new target for lowering non-HDL cholesterol
por: Hassan, Mohamed, et al.
Publicado: (2016)

The EMPEROR-Reduced trial: SGLT2 inhibitors for heart failure get more support
por: Wagdy, Kerolos
Publicado: (2020)

Takotsubo cardiomyopathy: A potentially serious trap (Data from the International Takotsubo Cardiomyopathy Registry)
por: Wagdy, Kerolos, et al.
Publicado: (2015)

Obesity and HFpEF
por: Clemenza, Francesco, et al.
Publicado: (2022)

DAPA-HF trial signals the birth of ‘diabetic cardiology’ and more
por: Wagdy, Kerolos, et al.
Publicado: (2020)

EMPEROR-Preserved: SGLT2 inhibitors breakthrough in the management of heart failure with preserved ejection fraction
por: Wagdy, Kerolos, et al.
Publicado: (2021)

PARIS: A good start for exercise in HFPEF
por: Elamragy, Ahmed A.
Publicado: (2014)

Focus on HFpEF in heart failure
por: He, Chunhui, et al.
Publicado: (2022)

Similarities and Differences Between HFmrEF and HFpEF
por: Li, Peixin, et al.
Publicado: (2021)

New aspects in cardiorenal syndrome and HFpEF
por: Méndez, Ana Belén, et al.
Publicado: (2022)

Benefits of peritoneal ultrafiltration in HFpEF and HFrEF patients
por: Grossekettler, Leonie, et al.
Publicado: (2020)

Locomotor and respiratory muscle abnormalities in HFrEF and HFpEF
por: Mangner, Norman, et al.
Publicado: (2023)

The Emerging Role of Cardiac Magnetic Resonance Imaging in the Evaluation of Patients with HFpEF
por: Webb, Jessica, et al.
Publicado: (2018)

Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
por: Borlaug, Barry A., et al.
Publicado: (2023)

Left-Side Pressure Index for All-Cause Mortality in Older Adults with HFpEF: Diagnostic Potential for HFpEF and Possible View for HFrEF
por: Hoshida, Shiro
Publicado: (2023)

Hemodynamic force assessment by cardiovascular magnetic resonance in HFpEF: A case-control substudy from the HFpEF stress trial
por: Backhaus, Sören J., et al.
Publicado: (2022)

Different determinants of exercise capacity in HFpEF compared to HFrEF
por: Batalli, Arlind, et al.
Publicado: (2017)

Editorial: HFpEF and HFmrEF: Different Sides of the Same Coin?
por: Martínez-Sellés, Manuel, et al.
Publicado: (2022)

Impaired Myocardial Bioenergetics in HFpEF and the Role of Antioxidants
por: Hiebert, John B., et al.
Publicado: (2016)

Diet-Induced Obesity HFpEF Murine Models
por: Carbone, Salvatore, et al.
Publicado: (2018)

A preclinical model for phenogroup 3 HFpEF
por: Yousefi, Keyvan, et al.
Publicado: (2019)

Decoding the Pathophysiology of HFpEF With High-Resolution Phenotyping
por: Houstis, Nicholas E.
Publicado: (2020)

Understanding HFpEF With Obesity: Will Pigs Come to the Rescue?
por: Kass, David A.
Publicado: (2021)

Turning Pressure Into Success: Preload Restriction in HFpEF?
por: Atkins, Jessica, et al.
Publicado: (2021)

Renin Feedback Is an Independent Predictor of Outcome in HFpEF
por: Binder, Christina, et al.
Publicado: (2021)

Targeting Collagen Pathways as an HFpEF Therapeutic Strategy
por: Bonanni, Alice, et al.
Publicado: (2023)

The role of imaging in the selection of patients for HFpEF therapy
por: Baron, Tomasz, et al.
Publicado: (2023)

Are HFpEF and HFmrEF So Different? The Need to Understand Distinct Phenotypes
por: Palazzuoli, Alberto, et al.
Publicado: (2021)

Reply: Diet-Induced Obesity HFpEF Murine Models
por: Valero-Muñoz, Maria, et al.
Publicado: (2018)

Cardiometabolic Heart Failure and HFpEF: Still Chasing Unicorns
por: Sharp, Thomas E., et al.
Publicado: (2019)

Microvascular and lymphatic dysfunction in HFpEF and its associated comorbidities
por: Cuijpers, Ilona, et al.
Publicado: (2020)

Cat-apulting Toward a Molecular Understanding of HFpEF
por: Robinson, Emma L., et al.
Publicado: (2021)

Hemodynamic force analysis is not ready for clinical trials on HFpEF
por: Arvidsson, Per M., et al.
Publicado: (2022)

Leukocyte count and the risk of adverse outcomes in patients with HFpEF
por: Zhu, Zhaowei, et al.
Publicado: (2021)

Tolerating Large Preclinical Models of HFpEF But Without the Intolerance?
por: Justo da Silva, Gustavo Jose, et al.
Publicado: (2021)

Structural and Hemodynamic Changes of the Right Ventricle in PH-HFpEF
por: Barilli, Maria, et al.
Publicado: (2022)

New antidiabetic therapy and HFpEF: light at the end of tunnel?
por: Tadic, Marijana, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1ot1nt1nvavql8la9cnsg6p6en